☆ 4.4 Article

Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance

CURRENT OPINION IN PHARMACOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Microbiology

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Allison J. Greaney et al.

Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.

CELL HOST & MICROBE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Genetic Variants of SARS-CoV-2-What Do They Mean?

Adam S. Lauring et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Tyler N. Starr et al.

Summary: Research has found that mutations in the receptor binding domain (RBD) of SARS-CoV-2 may potentially escape the action of the REGN-COV2 cocktail, providing important information for interpreting mutations observed during viral surveillance.

SCIENCE (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development

Chiranjib Chakraborty et al.

Summary: This article explores the protein drug targets and drug discovery approaches for SARS-CoV-2, focusing on drug repurposing studies, design of viral entry inhibitors, and development of different enzymes. By conducting comprehensive literature searches, the structural landscape of viral and host proteins is illustrated, providing insights for understanding drug targets and structure-based drug discovery for SARS-CoV-2.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance

Aditya K. Padhi et al.

Summary: With the use of mutational mapping, it was predicted that only a few mutations in the nsp12 subunit of RdRp are needed for SARS-CoV-2 to develop resistance to remdesivir. Certain mutations resulted in decreased binding affinity to remdesivir, indicating drug resistance. Identifying potential hotspot residues prone to mutation improves our understanding of SARS-CoV-2 drug resistance and COVID-19 pathogenesis.

ISCIENCE (2021)

添加到收藏夹

Article Microbiology

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Zhuoming Liu et al.

Summary: The study found that antibodies targeting the SARS-CoV-2 spike protein have escape mutations, different monoclonal antibodies have unique resistance profiles, some mutants are resistant to multiple antibodies while some variants can escape neutralization by convalescent sera. Comparing antibody-mediated mutations with circulating SARS-CoV-2 sequences revealed substitutions that may weaken neutralizing immune responses in some individuals, warranting further investigation.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: The E484K mutation and the risks it poses

Jacqui Wise

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir

Ross Martin et al.

Summary: The study reveals low genetic variation in the RNA replication complex of SARS-CoV-2, especially the RNA-dependent RNA polymerase (nsp12), which is the main target of remdesivir. The risk of pre-existing resistance to remdesivir is minimal.

ANTIVIRAL RESEARCH (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann et al.

Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.

CELL (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies

Chiranjib Chakraborty et al.

Summary: The rapid spread of SARS-CoV-2 globally has highlighted the need for effective treatment options. Drug repurposing of existing medications has become a key strategy in managing COVID-19 patients. Clinical trials conducted across multiple countries have shown promising results in antiviral and immunotherapeutic treatments, indicating the importance of further research in this area.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Editorial Material Medicine, Research & Experimental

D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin?

Chiranjib Chakraborty et al.

MOLECULAR THERAPY-NUCLEIC ACIDS (2021)

添加到收藏夹

Article Virology

Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil

Ronaldo da Silva Francisco Jr et al.

Summary: The emergence of novel SARS-CoV-2 lineages, including B.1.1.28 (E484K), in Rio Grande do Sul, Brazil has raised global concerns. Co-infection events and the identification of a new sample cluster named VUI-NP13L underscore the importance of strict and effective social distancing measures to combat the spread of potentially more hazardous SARS-CoV-2 strains.

VIRUS RESEARCH (2021)

添加到收藏夹

Article Microbiology

Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance

Alfredo Mari et al.

Summary: Various antiviral treatments for COVID-19, including repurposed drugs, have been investigated. The RNA-dependent RNA polymerase of SARS-CoV-2 has been targeted by inhibitors like remdesivir, but potential resistance mutations are rare and unlikely to destabilize the polymerase. This suggests that monitoring for drug resistance during the pandemic is crucial for global efforts.

MICROORGANISMS (2021)

添加到收藏夹

Article Immunology

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

Frauke Muecksch et al.

Summary: This study examined the development of antibodies following infection with the coronavirus, finding that evolved antibodies had increased affinity and neutralization potency, altered mutational pathways for viral resistance, and restricted neutralization escape options. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying populations of the virus and other pandemic threat coronaviruses.

IMMUNITY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations

Shane Miersch et al.

Summary: Bivalent and tetravalent nAbs have shown to be more effective in combating COVID-19 variants, with similar stability and specificity to approved antibody drugs.

JOURNAL OF MOLECULAR BIOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

添加到收藏夹

Review Microbiology

SARS-CoV-2 variants, spike mutations and immune escape

William T. Harvey et al.

Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.

NATURE REVIEWS MICROBIOLOGY (2021)

添加到收藏夹

Article Microbiology

Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants

Chiranjib Chakraborty et al.

Summary: The study analyzes the evolutionary patterns, geographical distributions, and transmission patterns of multiple emerging SARS-CoV-2 variants, as well as their impact on public health, including mutations within each lineage. The B.1.1.7 lineage shows the highest transmission frequency, and critical mutations (such as E484K, K417T/N, N501Y, and D614G) may affect vaccine efficacy. The findings will help in strategizing future pandemic planning, developing next-generation vaccines, and planning vaccination programs globally.

MBIO (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Allison J. Greaney et al.

Summary: The study found that although the human immune system can produce antibodies that target diverse RBD epitopes, in practice, the polyclonal response to infection tends to be skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Microbiology

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2

Agnieszka M. Szemiel et al.

Summary: This study selected drug-resistant SARS-CoV-2 populations with decreased sensitivity to remdesivir (RDV) in vitro, identifying a mutation in NSP12 that decreases RDV sensitivity. There is no evidence of widespread transmission of RDV-resistant mutants among globally circulating SARS-CoV-2 variants. Additionally, emerging SARS-CoV-2 variants showed substitutions at Spike sites corresponding to those identified in vitro, indicating their potential to arise without immune selection.

PLOS PATHOGENS (2021)

添加到收藏夹

Letter Immunology

Genomic Sequencing of SARS-CoV-2 E484K Variant B.1.243.1, Arizona, USA

Peter T. Skidmore et al.

Summary: Genomic surveillance is crucial in early detection of new SARS-CoV-2 variants, with the identification of an emergent variant B.1.243.1 carrying the E484K mutation highlighting the importance of real-time surveillance in informing public health responses.

EMERGING INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Virology

Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach

Manojit Bhattacharya et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More

Abinit Saha et al.

ARCHIVES OF MEDICAL RESEARCH (2020)

添加到收藏夹

Article Microbiology

Identification of Human Single-Domain Antibodies against SARS-CoV-2

Yanling Wu et al.

CELL HOST & MICROBE (2020)

添加到收藏夹

Article Medicine, General & Internal

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Yan Wu et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Meng Yuan et al.

SCIENCE (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Maria Pachetti et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Bin Ju et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Microbiology

Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment

Takahiko Koyama et al.

PATHOGENS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Qianqian Li et al.

CELL (2020)

添加到收藏夹

Article Immunology

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Emilie Seydoux et al.

IMMUNITY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells

Rolando Cannalire et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Immunology

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Fabian Schmidt et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu et al.

NATURE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Jiangdong Huo et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Xiangyang Chi et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Thomas F. Rogers et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Christopher O. Barnes et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction

Leo Hanke et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Editorial Material Engineering, Biomedical

Neutralizing antibodies for the treatment of COVID-19

Shibo Jiang et al.

NATURE BIOMEDICAL ENGINEERING (2020)

添加到收藏夹

Article Biology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Yiska Weisblum et al.

ELIFE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Robert N. Kirchdoerfer et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Article Multidisciplinary Sciences

One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities

Lorenzo Subissi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.